What I don't yet understand is how MSCs work. Maybe someone with a medical background can explain.
Is the MSCs for the treatment of Acute GvHD, CLI, Osteoarthritis (and others) all produced exactly the same way, as in they are all identical.
I know we have to prove MSCs work for CLI, and Osteoarthritis, but lets say the trial is successful.
Will the end product be one MSCs solution produced by the CYP technology which would treat all three (for now) conditions?
Or do the MSCs would have to be tailored for each treatment?
Ann: CYP Files Application to Commence Phase 2 CLI Clinical Trial, page-36
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $45.80M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 25.5¢ | 25.5¢ | $313 | 1.229K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 22209 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 36715 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |